Novel CAR-T for Glioblastoma Induced ‘Dramatic’ Responses in Early Trial

Source link :

A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]

Author : News Health

Publish date : 2024-03-13 17:39:30

Copyright for syndicated content belongs to the linked Source.